Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Key Points Viking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. The medicine could eventually become a notable player in the weight-loss market. Viking Therapeutics' prospects look promising, but there are significant risks to consider. 10 stocks we like better than Viking Therapeutics › Investors looking to capitalize on the rapidly expanding weight loss drug market have increasingly more options. Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are still the leaders, but several other drugmakers are making significant clinical headway. One of them is Viking Therapeutics (NASDAQ: VKTX) , a clinical-stage biotech.